期刊文献+

我国华南地区MuSK抗体阳性重症肌无力患者的临床特点 被引量:6

Clinical characteristics of MuSK antibody positive myasthenia gravis patients in Southern China
下载PDF
导出
摘要 目的分析我国华南地区骨骼肌特异性酪氨酸激酶抗体(MuSK-Ab)阳性重症肌无力(myasthenia gravis,MG)的临床特点。方法回顾性收集2017年8月至2019年8月在中山大学附属第一医院确诊的住院MuSK抗体阳性MG(MuSK-MG)患者26例,并选取同期收治的乙酰胆碱受体抗体(AChR-Ab)阳性MG(AChR-MG)患者157例作为对照组,比较两组患者临床特点以及对治疗反应的差异。结果与AChR-MG患者比较,MuSK-MG患者女性构成(80.8%比58.0%,P<0.05)、平均发病年龄〔(43.12±13.02)岁比(36.04±17.97)岁,P<0.05〕高,球部肌受累(96.2%比70.1%,P<0.01)和肌无力危象(myasthenic crisis,MC;61.4%比28.7%,P<0.05)更常见。两组患者新斯的明试验阳性率(61.5%比70.7%)、低频重复神经电刺激(RNS)阳性率(78.3%比83.3%)比较差异无统计学意义(均P>0.05)。在治疗反应方面,胆碱酯酶抑制剂(AChEIs)对MuSK-MG患者的有效率低于AChR-MG患者(16.0%比58.6%,P<0.01)。两组患者发生MC期间,对血浆置换(PLEX)的反应优于静脉注射丙种球蛋白(IVIG)。结论我国华南地区MuSK-MG以40岁左右女性多见,与AChR-MG比较易累及球部肌和呼吸肌,容易发生MC。MuSK-MG对AChEIs的反应性低于AChR-MG。RNS对我国华南地区MuSK-MG诊断的敏感性与AChR-MG比较无统计学差异,但高于欧美人群。PLEX在MuSK-MG患者的危象前或危象状态中的应用可显著缓解病情。 Objective To analyze the clinical characteristics of skeletal muscle specific tyrosine kinase antibody(MuSK-Ab)positive myasthenia gravis(MG)in Southern China.Methods From August 2017 to August 2019,26 MG inpatients with MuSK-Ab(MuSK-MG group)diagnosed in the first affiliated hospital of Sun Yat-Sen University were reviewed and 157 MG inpatients with acetylcholine receptor antibody(AChR-Ab)were selected as a control group(AChR-MG group).The clinical characteristics and treatment response of the two groups were compared.Results Compared with the AChR-MG patients,the female composition(80.8%vs.58.0%,P<0.05)and average onset age [(43.12±13.02)years vs.(36.04±17.97)years,P<0.05]of the MuSK-MG patients were higher.Bulbar muscle involvement(96.2% vs.70.1%,P <0.01)and myasthenic crisis(MC)(61.4% vs.28.7%,P<0.05)of the MuSK-MG group were more common than the AChR-MG group.There was no significant difference in the positive rate of neostigmine test(61.5%vs.70.7%,P>0.05)or low frequency repetitive nerve stimulation(RNS)(78.3%vs.83.3%,P>0.05)between the two groups.In terms of therapeutic response,the effective rate of cholinesterase inhibitors(AChEIs)in the MuSKMG patients was lower than that in the AChR-MG patients(16.0%vs.58.6%,P<0.01).During the period of MC,the response to PLEX in the two groups was superior to intravenous immunoglobulin(IVIG).Conclusions In Southern China,MuSK-MG patients are more common in 40 years old women.They are more likely to present bulbar muscles and respiratory muscle weakness than AChR-MG patients.And MC is more likely to occur in MuSK-MG patients.The sensitivity of RNS to MuSK-MG in Southern China is similar to AChR-MG and higher than that in Europe and the United States.The efficacy of AChEIs in MuSK-MG patients is lower than AChR-MG.The application of PLEX in MuSK-MG patients in the state of crisis or pre-crisis can significantly relieve the condition.
作者 鲁亚茹 欧昶毅 邱力 林中强 黄志东 刘卫彬 LU Yaru;OU Changyi;QIU Li;LIN Zhongqiang;HUANG Zhidong;LIU Weibin(Department of Neurology,National Key Clinical Department and Key Discipline of Neurology,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China)
出处 《中国神经免疫学和神经病学杂志》 CAS 北大核心 2020年第1期15-19,共5页 Chinese Journal of Neuroimmunology and Neurology
基金 国家自然科学基金资助项目(81873772) 国家自然科学基金重点国际(地区)合作研究项目(81620108010) 中山大学临床研究5010计划项目(2010003)
关键词 重症肌无力 MuSK抗体 乙酰胆碱受体抗体 肌无力危象 华南地区 myasthenia gravis skeletal muscle specific tyrosine kinase antibody acetylcholine receptor antibody myasthenic crisis Southern China
  • 相关文献

参考文献3

二级参考文献18

  • 1刘卫彬,王化冰,许贤豪.重症肌无力//王维治.神经病学.北京:人民卫生出版社.2013:1509-1544.
  • 2Smolen JS,Aletaha D,Bijlsma JW,Breedveld FC,Boumpas D,Burmester G,Combe B,Cutolo M,de Wit M,Dougados M,Emery P,Gibofsky A,Gomez-Reino J J,Haraoui B,Kalden J,Keystone EC,Kvien TK,McInnes I,Martin-Mola E,Montecucco C,Schoels M,van der Heijde D; T2T Expert Committee.Treating rheumatoid arthritis to target:recommendations of an international task force.Ann Rheum Dis,2010,69:631-637.
  • 3Gregersen PK,Kosoy R,Lee AT,Lamb J,Sussman J,McKee D,Simpfendorfer KR,Pirskanen-Matell R,Piehl F,PanHammarstrom Q,Verschuuren J J,Titulaer M J,Niks EH,Marx A,Str(o)bel P,Tackenberg B,Pütz M,Maniaol A,Elsais A,Tallaksen C,Harbo HF,Lie BA,Raychaudhuri S,de Bakker PI,Melms A,Garchon H J,Willcox N,Hammarstrom L,Seldin MF.Risk for myasthenia gravis maps to a (151) pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.Ann Neurol,2012,72:927-935.
  • 4Li X,Xiao BG,Xi JY,Lu CZ,Lu JH.Decrease of CD4(+)CD25 (high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis.Clin Immunol,2008,126:180-188.
  • 5Marx A,Willcox N,Leite MI,Chuang WY,Schalke B,Nix W,Str(o)bel P.Thymoma and paraueoplastic myasthenia gravis.Autoimmunity,2010,43(5/6):413-427.
  • 6Zhou L,Chong MM,Littman DR.Plasticity of CD4 +T cell lineage differentiation.Immunity,2009,30:646-655.
  • 7Balandina A,Lécart S,Dartevelle P,Saoudi A,Berrih-Aknin S.Functional defect of regulatory CD4(+)CD25 + T cells in the thymus of patients with autoimmune myasthenia gravis.Blood,2005,105:735-741.
  • 8Thiruppathi M,Rowin J,Li Jiang Q,Sheng JR,Prabhakar BS,Meriggioli MN.Functional defect in regulatory T cells in myasthenia gravis.Ann NY Acad Sci,2012,1274:68-76.
  • 9Luo C,Li Y,Liu W,Feng H,Wang H,Huang X,Qiu L,Ouyang J.Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis.J Neuroimmunol,2013,256(1/2):55-61.
  • 10Sri-udomkajorn S, Panichai P,Liumsuwan S.Childhood myasthenia gravis:clinical features and outcomes.J Med Assoc Thai,2011,94 Suppl 3:152-157.

共引文献19

同被引文献37

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部